Updates in the Management of CLL/SLL: Management of Relapsed/Refractory Disease and the Role of Minimal Residual Disease
The therapeutic landscape of chronic lymphocytic leukemia (CLL) has evolved significantly in recent years, and the use of targeted therapy with small molecule inhibitors in the first-line setting will significantly alter the management of relapsed/refractory disease.
  • Chronic Lymphocytic Leukemia
  • Recorded Webcast
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation